Compare Medpace Holdings Inc (MEDP) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Southern Copper Corp — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Southern Copper Corp trades at $194.99 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 9.7× Medpace Holdings Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | SCCO | |
|---|---|---|
Market Cap | $16.90B | $164.21B |
Sector | Technology | Basic Materials |
52-Week High | $620.59 | $218.85 |
52-Week Low | $393.42 | $93.70 |
Enterprise Value | $16.52B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Southern Copper (SCCO) trades at $194.86, down 2.62% on the day, with a bullish technical signal from moving averages and strong support at $191. The company reported record Q2 2026 earnings, beating estimates with EPS of $1.99, driven by high metal prices, though production volumes declined. Revenue and net income have grown consistently, with 2025 revenue at $13.42B and net income at $4.33B, reflecting a net margin of 35.87%.
Outlook remains positive due to robust profitability and AI-driven copper demand, but risks include premium valuation (P/E 29.18), reliance on metal prices, and mixed analyst sentiment with a consensus price target of $153.64 below current levels. Institutional buying and strong cash flow trends support growth, yet investors face volatility from commodity cycles and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
